Sustainable and Scalable Strategies for Safe and Effective Administration of Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma in Outpatient and Community Settings

Multiple myeloma (MM) remains incurable. Despite advances in treatment and aggressive first-line therapy, most patients relapse. The pursuit for tolerable and effective treatments for heavily treated patients in the relapsed/refractory (R/R) setting has resulted in novel targets and therapies, including four bispecific antibodies (BsAbs).

Because these agents have unique adverse event profiles which can be life-threatening, patients are typically hospitalized during step-up dosing to ensure proper pretreatment, monitoring, and supportive care. Many institutions are piloting outpatient administration of BsAbs to increase access to, reduce inpatient hospitalizations, lower overall healthcare costs, and enhance patients’ experiences. Yet administration of BsAbs in community settings is challenged by lack of experience coupled with requirements for multidisciplinary care and poorly aligned infrastructures.

This activity supports community providers in assessing their infrastructure, protocols, and workforce to implement the clinical and operational elements necessary for safe and effective outpatient BsAb administration.

This activity also engages academic providers to support improved care coordination and transitions as well as mentoring of community specialists.
 
Educational Partner: Academy for Continued Healthcare Learning (ACHL)

Medium:  Online

Commercial Support: Supported by an educational grant provided by Johnson & Johnson.

Target Audience

This educational activity is designed for community and academic hematologists/oncologists, as well as hematology/oncology clinical pharmacists, NPs and PAs in the oncology setting, oncology nurses and other members of the multidisciplinary rapid response team including members of the ED, ICU, and infectious disease teams in the community settings who care for/manage patients with R/R MM.

Learning Objectives

Upon completion of this activity, learners will be able to:

Community Oncology Sites:

  • Align site infrastructure and build clinical capacity for safe and effective BsAb administration in community settings to address patient selection, step-up dosing criteria, treatment maintenance, and AE monitoring and management protocols;
  • Develop transition of care protocols to and from academic center providers to address referrals of eligible patients and outpatient administration of BsAbs;
  • Establish multidisciplinary care pathways, workflows, and training requirements to ensure optimal alignment to evidence-based care at each step in the treatment process.

Individual multidisciplinary learners practicing in community settings:

  • Integrate the latest evidence-based decision support tools and strategies to formulate individualized management plans for patients with R/R MM;
  • Employ strategies to prevent, monitor, and manage AEs associated with BsAbs;
  • Adopt patient-centric education and communication materials on BsAbs for the treatment of R/R MM.

Individual hematologists/oncologists in academic settings:

  • Foster a culture of mentorship and leadership to facilitate learning and optimal coordination of care between community and academic centers;
  • Develop transition of care protocols to outpatient community providers to address treatment maintenance and AE monitoring and management protocols.
Additional information
ACGME/ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
Interpersonal and Communication Skills
For more information, please contact:
CME Coordinator Contact Name: 
Nora Eldasher
CME Coordinator Contact Email: 
Summary
Activity opens: 
04/10/2026
Activity expires: 
04/10/2027
FACULTY
Nazila Shafagati, MD
Clinical Associate of Medicine
University of Chicago
Chicago, IL
 
Benjamin Derman, MD
Associate Professor
Medicine, Section of Hematology/Oncology
University of Chicago
Chicago, IL
 
Brittany McArn, OPN-CG, CPPN
Financial Navigation Manager
Outpatient Oncology Services
FirstHealth of the Carolinas
Pinehurst, NC
 
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
The University Of Chicago Pritzker School Of Medicine designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Physician assistants (PAs), nurse practitioners (NPs), and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.


Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
Registration: To view this activity, visit the main activity page.
If you are logged in, click on the "Complete Activity" button below!
 
Please login or create an account to proceed.